Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A New Biomarker for Predicting the Abscopal Effect: Quantifying Polyclonal Effector Tumor Antigen-Specific T Cells by Using Nanoparticles Loading Whole Tumor Antigens.

Analytical chemistry·2025

Same author

High baseline levels of PD-L1 reduce the heterogeneity of immune checkpoint signature and sensitize anti-PD1 therapy in lung and colorectal cancers.

Cell death & disease·2025

Same author

Baseline tumour vessel perfusion as a non-invasive predictive biomarker for immune checkpoint therapy in non-small-cell lung cancer.

BMJ oncology·2025

Same author

Fractionated radiotherapy initiated at the early stage of bone metastasis is effective to prolong survival in mouse model.

Cancer biology & therapy·2025

Same author

Optical Surface Management System and BladderScan for Patient Setup During Radiotherapy of Postoperative Prostate Cancer.

BioMed research international·2024

Same author

Alleviating hypoxia to improve cancer immunotherapy.

Oncogene·2023

Search research articles

Related Experiment Video

Updated: Aug 5, 2025

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Published on: September 3, 2021

Vascular Normalization Was Associated with Colorectal Tumor Regression upon Anti-PD-L1 Combinational Therapy.

Yan Zhang^1,2, Jiayan Gao¹, Yan He²

¹The Aoyang Cancer Institute, The Affiliated Aoyang Hospital of Jiangsu University, Zhangjiagang, 215617 Jiangsu, China.

Journal of Immunology Research

|March 27, 2023

Summary

Combining anti-PD-L1 therapy with CD4+ T cell depletion promotes colorectal tumor regression and vascular normalization. This approach enhances CD8+ T cell activity, overcoming immunosuppression for improved cancer immunotherapy outcomes.

More Related Videos

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Related Experiment Videos

Last Updated: Aug 5, 2025

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Published on: September 3, 2021

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Area of Science:

Immunology
Oncology
Cancer Therapy

Background:

Anti-PD-L1 therapy shows limited efficacy in many cancer patients due to the immunosuppressive tumor microenvironment (TME).
The TME presents a significant barrier to successful cancer immunotherapy.
Understanding the interplay between immune cells and tumor vasculature is crucial for improving treatment outcomes.

Purpose of the Study:

To investigate the combined effects of anti-PD-L1 therapy and CD4+ T cell depletion on colorectal tumor regression and vascular normalization.
To elucidate the impact of this combination therapy on immune cell populations within the TME.
To determine the role of CD8+ T cells in mediating the anti-tumor effects of anti-PD-L1 therapy.

Main Methods:

Utilized a colorectal tumor model in mice.
Administered anti-PD-L1 therapy alone and in combination with CD4+ T cell depletion.
Analyzed tumor regression, vascular normalization, and immune cell populations (including CD4+, CD8+, PD-L1+ cells) within the TME using flow cytometry and other immunological techniques.

Main Results:

Combined anti-PD-L1 therapy and CD4+ T cell depletion induced significant colorectal tumor regression and vascular normalization, unlike monotherapy.
This combination therapy eradicated intratumoral PD-L1+ lymphoid and myeloid cells.
The treatment elevated proportions of activated and memory CD8+ T cells, suggesting enhanced anti-tumor immunity.
Anti-PD-L1 therapy's tumor suppressive effects were dependent on CD8+ T cells and antagonized by CD4+ T cells.

Conclusions:

Anti-PD-L1 therapy, when combined with CD4+ T cell depletion, promotes colorectal tumor regression and vascular normalization.
CD8+ T cells are critical mediators of these anti-tumor effects, while CD4+ T cells appear to antagonize them.
This combination strategy offers a promising new approach to enhance the efficacy of anti-PD-L1 immunotherapy in colorectal cancer.